Doxorubicin Hydrochloride → Ethyl 2-{[(3S)-1-({[1-(2-tert.butoxy-2-oxoethyl)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]amino}carbonyl)cyclopentyl]methyl}-4-(isopropylamino)-4-oxobutyrate

HRID 32350

反応式

[C:1]([O:5][C:6](=[O:40])[CH2:7][N:8]1[C:14]2[CH:15]=[CH:16][CH:17]=[CH:18][C:13]=2[CH2:12][CH2:11][C@H:10]([NH:19][C:20]([C:22]2([CH2:27]CC(C(OCC)=O)CC(O)=O)[CH2:26][CH2:25][CH2:24][CH2:23]2)=[O:21])[C:9]1=[O:39])([CH3:4])([CH3:3])[CH3:2].C[C@@H]1[O:47][C@@H:46]([O:48][C@@H:49]2[C:54]3=C(O)C4C(=O)C5C(=CC=CC=5OC)C(=O)C=4C(O)=C3C[C@@](O)(C(CO)=O)C2)[CH2:45][C@H:44](N)[C@@H:43]1[OH:79].Cl>CO>[C:1]([O:5][C:6](=[O:40])[CH2:7][N:8]1[C:14]2[CH:15]=[CH:16][CH:17]=[CH:18][C:13]=2[CH2:12][CH2:11][C@H:10]([NH:19][C:20]([C:22]2([CH2:27][CH:45]([CH2:44][C:43]([NH:8][CH:14]([CH3:15])[CH3:13])=[O:79])[C:46]([O:48][CH2:49][CH3:54])=[O:47])[CH2:23][CH2:24][CH2:25][CH2:26]2)=[O:21])[C:9]1=[O:39])([CH3:4])([CH3:3])[CH3:2]

参加物

実験手順

With a retention time of 6.5 min., there was obtained 33 g of the second stereoisomer, which was assigned the designation “rel2” in relation to the chiral center “*Ca” bearing the group “—COOR1”, as (2“rel2”)-3-{[1-({[(3S)-1-(2-tert.butoxy-2-oxoethyl)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]amino}carbonyl)cyclopentyl]ethyl}-4-ethoxy-4-oxobutyric acid, 1H-NMR (CDCl3): 7.31-7.17, m, [3]; 7.11, d, [2]; 6.81, d, [1]; 4.60, 4.56, 4.35, 4.31, AB-Q. [2]; 4.48, m, [1]; 4.10, m, [1]; [α]D=−136° (1% in methanol).

後処理

customWith a retention time of 6.5 min., there was obtained 33 g of the second stereoisomer, which

出典と根拠

ORDレコード: ord-1a98a909efdd4839a613a93fa2b72903
出典データセット: uspto-grants-2008_09
DOI: 10.6084/m9.figshare.5104873.v1
特許番号: US07427611B2

反応式

参加物

反応物 2

生成物 1

試薬・触媒・溶媒 1

実験手順

後処理

出典と根拠

関連ノート